Sign in to fuzzto save your conversations, follow your research and come back anytime.
Emami
SectorFMCG
Emami Limited is a leading Indian FMCG company that manufactures and markets personal care and healthcare products. The company offers over 300 products across categories including hair care, skin creams, soaps, lotions, talcum powder, and ayurvedic healthcare products. Emami's portfolio includes well-known brands such as Navratna, BoroPlus, Fair & Handsome, Zandu Balm, and Kesh King. The company has a strong distribution network with products available in over 940,000 retail outlets across India and a global presence in more than 60 countries. Emami operates 8 manufacturing units in India and 1 in Bangladesh, with facilities certified for cGMP and ISO 9001:2000 standards. The company has expanded through acquisitions and new product launches, entering markets such as male grooming, feminine hygiene, and home hygiene products. Emami has also invested in strategic partnerships and subsidiaries to strengthen its market position and product offerings.
In the news
Emami's ₹282 cr buyback supports D2C growth strategy amid challenges
Emami shares jump 4% on ₹282 cr buyback plan at ₹475/share
Emami Shares Surge 7% as Board Approves ₹282 Cr Buyback at ₹475/share
Emami's BoroPlus launches baby-care range 'FromMaa' in ₹40,000-crore market
Emami Agrotech invests ₹750 cr in food park, eyes IPO
Prabhudas Lilladher cuts Emami target to ₹443, holds rating
Emami Q1 FY27: Net profit drops 16.4% to ₹137.35 cr amid margin pressure
Emami Agrotech targets ₹22,000 cr turnover in FY27
HDFC Life drops 5th straight session, down 23% YoY
Emami Q4 Results: Brokerages Bullish Despite 11.7% Profit Decline
Prabhudas Lilladher cuts Emami to Hold, sets ₹469 target
Max Healthcare shares drop 7% despite 7.2% profit growth in Q4
Emami Q4FY26: Net profit drops 11.72% to ₹143.17 crore
Refex Industries posts ₹9.96 cr Q4 loss, full-year loss at ₹42.02 cr
Emami acquires 60% stake in Vedix, SkinCraft parent for ₹321 cr
Emami acquires 60% stake in Vedix, SkinKraft for ₹321 crore
Emami Shows Growth Turnaround with Bright Prospects
Motilal Oswal Sets Emami Target at ₹650 on Strong Q3 Growth
Emami Q3 Results: Stock surges 9% on strong 15% PAT growth
The Quarter story
The two most recent quarterly results, compared side-by-side.
Emami sustains top-line growth and core profitability, but rising input costs and financing expenses compress margins.
Net sales grew from ₹893.1 Cr to ₹1,030.1 Cr from Q1 FY26 to Q1 FY27, sustaining top-line momentum.
Gross margin slipped from 69.4% to 65.8% from Q1 FY26 to Q1 FY27, indicating input cost inflation.
EBITDA rose from ₹214.2 Cr to ₹226.2 Cr from Q1 FY26 to Q1 FY27, reflecting steady operational earnings.
COGS rose from 29.4% to 34.2% from Q3 FY26 to Q1 FY27, squeezing profitability.
Brand amortisation fell from ₹22.8 Cr to ₹18.8 Cr from Q1 FY26 to Q1 FY27, easing cost pressure.
International contribution dropped from 16% to 12% from Q1 FY26 to Q1 FY27, weakening global revenue mix.
Interest expense climbed from ₹2.4 Cr to ₹5.6 Cr from Q1 FY26 to Q1 FY27, raising financing costs.
Company insights, generated from the most recent coverage.
Trading window closed from Oct 1 until 48 hours after Q2 FY27 results — pre-results uncertainty is the main near-term overhang, with the market bracing for a second straight quarter of margin pressure.
International business fell 12% in INR terms in Q1 FY27 with no recovery signal yet, making overseas operations the key swing factor against Emami's domestic 20% growth story.
Buyback approved Sept 17, 2026 lifted the stock only to ₹376; it has since slipped below pre-announcement levels, so the buyback has failed to establish a price floor and reads as 'sell the news'.